VivoSeq
Oncology

Plasmacytoma

7

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Plasmacytoma is an early-stage landscape with 7 programs across 5 companies. The most active players are AstraZeneca, Bristol-Myers Squibb, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

0/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3Takeda logo

Takeda

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Active, not recruiting2 · 29%
Withdrawn1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06863584·41 enrolled
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07115667·21 enrolled
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05248633·220 enrolled
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04174196·21 enrolled
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Active, not recruiting·UUniversity College, London·Phase 3·NCT02544308·36 enrolled
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Terminated·Alliance for Clinical Trials in Oncology·Phase 3·NCT02516423·11 enrolled
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03196401

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)